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Article

Activation of LXRb inhibits tumor respiration and is
synthetically lethal with Bcl-xL inhibition
Trang Thi Thu Nguyen1, Chiaki Tsuge Ishida1, Enyuan Shang2, Chang Shu1, Consuelo Torrini1,
Yiru Zhang1, Elena Bianchetti1, Maria J Sanchez-Quintero3, Giulio Kleiner3, Catarina M Quinzii3
Mike-Andrew Westhoff4, Georg Karpel-Massler5, Peter Canoll1 & Markus D Siegelin1,*

,

Abstract

Introduction

Liver-X-receptor (LXR) agonists are known to bear anti-tumor
activity. However, their efficacy is limited and additional insights
regarding the underlying mechanism are necessary. By performing
transcriptome analysis coupled with global polar metabolite
screening, we show that LXR agonists, LXR623 and GW3965,
enhance synergistically the anti-proliferative effect of BH3
mimetics in solid tumor malignancies, which is predominantly
mediated by cell death with features of apoptosis and is rescued
by exogenous cholesterol. Extracellular flux analysis and carbon
tracing experiments (U-13C-glucose and U-13C-glutamine) reveal
that within 5 h, activation of LXRb results in reprogramming of
tumor cell metabolism, leading to suppression of mitochondrial
respiration, a phenomenon not observed in normal human astrocytes. LXR activation elicits a suppression of respiratory complexes
at the protein level by reducing their stability. In turn, energy starvation drives an integrated stress response (ISR) that up-regulates
pro-apoptotic Noxa in an ATF4-dependent manner. Cholesterol
and nucleotides rescue from the ISR elicited by LXR agonists and
from cell death induced by LXR agonists and BH3 mimetics. In
conventional and patient-derived xenograft models of colon carcinoma, melanoma, and glioblastoma, the combination treatment of
ABT263 and LXR agonists reduces tumor sizes significantly stronger
than single treatments. Therefore, the combination treatment of
LXR agonists and BH3 mimetics might be a viable efficacious treatment approach for solid malignancies.

Advanced solid malignancies, such as glioblastoma (GBM; Hegi
et al, 2005), metastatic melanoma, and colon cancer, remain challenging to treat. These recalcitrant neoplasms require novel more
efficient and less toxic therapies. In this report, we are introducing a
novel approach to address this pivotal issue.
It has been known for some time that tumor cells organize their
metabolism distinct from non-neoplastic cells. Representing the most
relevant feature in this context is undoubtedly aerobic glycolysis, a
paradoxical phenomenon that tumor cells bypass oxidative metabolism by converting glucose via pyruvate to lactate (Locasale et al,
2011; Masui et al, 2013; Viale et al, 2014; Pacold et al, 2016; Li et al,
2017). However, recent evidence shows that some tumor cells
depend on oxidative phosphorylation as well and indeed there are
several cancer cell lines that have a high dependency on cellular
respiration to maintain their survival (Dranoff et al, 1985; Qing et al,
2012; Willems et al, 2013; Agnihotri & Zadeh, 2016). Aside from
carbohydrate metabolism, there are known alterations in lipid metabolism in cancer (Agnihotri & Zadeh, 2016). In this regard, cholesterol and its derivatives and precursors have a central role for tumor
cells. This appears to be intuitive since malignant tumors display a
high proliferation rate, which requires the presence of cholesterol.
Liver-X-receptor (LXR) agonists represent a novel means to counteract cholesterol levels in tumor cells, including glioblastoma and
melanoma, by enhancing the excretion (increase in ABCA1) and at
the same time decreasing the resorption of cholesterol (decrease in
LDL receptor). Recently, GW3965 and LXR623 have demonstrated
anti-tumor efficacy in vitro and in vivo (Pencheva et al, 2014; Villa
et al, 2016). These effects were described to be primarily mediated
by LXRb since this receptor appeared to be predominantly expressed
over LXRa in most tumor cells (Villa et al, 2016; Wang et al, 2017).
Aside from metabolism, tumor cells maintain a deregulated cell
death machinery and have lost the ability to die in a physiological
manner. This feature is linked to resistance to apoptosis, a form of cell
death that is largely regulated by the pro- and anti-apoptotic Bcl-2
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family members (Lagadec et al, 2008; Souers et al, 2013; Chen et al,
2014; Kiprianova et al, 2015; Karpel-Massler et al, 2017c). Classical
anti-apoptotic members are Mcl-1, Bcl-2, and Bcl-xL. Through recent
discoveries, these molecules became readily targetable by a
compound class, called BH3 mimetics. Representative examples are
ABT263 and ABT199 (Tse et al, 2008; Souers et al, 2013). The latter
one has received FDA approval (Souers et al, 2013; Chan et al, 2015;
Johnson-Farley et al, 2015; Deeks, 2016; Lam et al, 2017).
Here, we provide evidence that BH3 mimetics and LXR623/
GW3965 (Pencheva et al, 2014; Villa et al, 2016) synergistically
reduce the viability of solid tumor cells in vitro and in vivo, mediated
by an early unexpected metabolic reprogramming of oxidative and
central carbon metabolism elicited by LXRb activation, which was
identified through a combined screen of gene set enrichment and
polar metabolite LC/MS analysis. Nota bene, the metabolic effects
on oxidative phosphorylation by LXR activation are not detectable in
normal human astrocytes, suggesting a cancer-specific vulnerability.

Results
ABT263 and liver-X-receptor agonists reduce cellular viability in a
synergistic manner by enhanced apoptosis accompanied by
cleavage of PARP and caspases
We initiated this study with a transcriptome and gene set enrichment analysis (GSEA), which demonstrated that LXR623 leads to
up-regulation of gene sets related to cholesterol efflux in human
glioblastoma and colonic carcinoma cells (Figs 1A and B, and
EV1A). Consistently, we noted an increase in genes related to
enhanced cholesterol synthesis (Figs 1C and EV1B). Moreover,
GSEA suggested enhanced priming for apoptosis with up-regulation
of pro-apoptotic Bcl-2 family members and an inhibition of mitochondrial metabolism (Figs 1D and EV1D–F). To validate these
observations further, U87 GBM cells were treated with increasing
concentrations of LXR623 and the protein expression of the ABCA1
transporter was determined (Fig EV1C). We found that LXR623
induced a dose-dependent increase in the cholesterol efflux transporter, resulting in a depletion of cholesterol levels in GBM cells
(Fig 1E). As anticipated, the cholesterol synthesis inhibitor, simvastatin, led to reduction of total cholesterol levels as well. We also
confirmed that indeed the depletion of cholesterol ultimately led to
cellular demise and found that LXR623-mediated cell death is
substantially rescued by exogenous administration of cholesterol
(Appendix Fig S1F). To assess the clinical relevance of these findings, we interrogated the TCGA database for colonic adenocarcinoma and grouped patients based on their expression level of
ABCA1. We found that patients with high ABCA1 mRNA levels
displayed lower levels of groups of genes related to mitochondrial
metabolism (electron transport chain) and mitochondrial translation/transcription (TFAM) (Figs 1F, EV1G–K, and EV2A and B).
These observations (GSEA findings) led us to hypothesize that LXR
agonists synergize with BH3 mimetics (ABT263). Therefore, we
conducted cellular viability assays with dose–responses of each drug,
followed by drug combination treatment and synergy analysis based
on the Chou–Talalay method, which enables the calculation of
normalized isobolograms (median-effect equation) (Chou, 2010;
Karpel-Massler et al, 2017c; Merino et al, 2017). Selected conditions

2 of 20

EMBO Molecular Medicine 11: e10769 | 2019

Trang Thi Thu Nguyen et al

of the single and combination treatments are provided and statistically
compared (Fig 1G–N and Appendix Fig S1A–E). Our results suggest
that LXR623 and ABT263 demonstrated a synergistic reduction of
cellular viability in patient-derived GBM xenograft cells, GBM12, and
established GBM cells, U87 (Fig 1G, H, K, and L, and Appendix Fig
S1A, B, and E). Similar results were observed in human colon carcinoma cells, HCT116 (Fig 1I and M, and Appendix Fig S1C and E).
Next, we assessed the anti-proliferative effects of a related compound
of the same drug category, GW3965 (Pencheva et al, 2014). This
compound was particularly active in melanomas. Therefore, we
treated A375 melanoma cells with ABT263, GW3965, or the combination of both and as above conducted cellular viability assays with
subsequent determination of CI values (CI values < 1 indicate synergism). Akin to the findings above, we found that ABT263 and
GW3965 had an overall synergistic effect on inhibition of cellular
proliferation (Fig 1J and N, and Appendix Fig S1D and E). To confirm
the role of cholesterol depletion in the combination treatment, we
treated glioblastoma cells with vehicle, LXR623, ABT263, or the
combination in the presence or absence of cholesterol. We detected a
significant protection from reduction in cellular viability when cholesterol was present, suggesting a potential role of cholesterol depletion
in the mechanism of the combination treatment (Appendix Fig S1G).
To demonstrate that the reduction in cellular viability is due to
apoptosis and that substantial cell death occurs, we conducted
annexin V/propidium iodide staining. In alignment with the cellular
viability assays, the combination treatment led to an enhanced fraction of annexin V-positive cells in U87, T98G, LN229, MeWo, and
HCT116 cells as well as in GBM stem-like cells (Fig 2A and B).
Comparable results were obtained in A375 and WC62 melanoma
cells (Appendix Fig S2). Apoptosis activation is preceded by loss of
mitochondrial membrane potential. Therefore, we analyzed mitochondrial membrane potential under the various treatment conditions. Our findings show that the combination treatment of LXR623
and ABT263 led to a significantly stronger disruption of mitochondrial membrane potential than each compound alone (Fig 2C and
D). Moreover, the ABT263 combined with LXR623 enhanced cleavage of PARP and caspase-9 (Fig 2E). These are all features that
support the notion that Bcl-xL/Bcl-2 inhibition and LXR receptor
activation engage in cell death with features of apoptosis. Next, we
asked the question which of the anti-apoptotic Bcl-2 family
members is responsible for the cell death induction in the combination treatment of LXR agonists and BH3 mimetics. To this end, we
took advantage of the recently developed selective BH3 mimetics,
such as ABT199 (selective Bcl-2 inhibitor), WEHI-539 (selective BclxL inhibitor), and A1210477 (selective Mcl-1 inhibitor) (KarpelMassler et al, 2017a). Utilizing HCT116 colon carcinoma and stemlike GBM cells, we found that inhibition of Bcl-xL was most relevant
to enhance the apoptotic effects of LXR agonists, followed by Mcl-1
and Bcl-2 inhibition (Figs 2F, and EV3A and B).
LXR623 and GW3965 modulate the expression of anti-apoptotic
Bcl-2 family members with a pronounced increase in Noxa
Given the synergy between LXR agonists and BH3 mimetics, we
were wondering about the underlying molecular mechanisms that
permit this phenomenon to occur. Given the importance of Bcl-2
family members on apoptosis and on sensitivity toward BH3
mimetics, we analyzed the expression of Bcl-2 family members in
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Figure 1. Combined treatment with ABT263 and LXR623 results in a synergistic anti-proliferative effect across solid tumor cells.
A–D HCT116 and U87 cells were treated with 20 µM LXR623 for 24 h. Transcriptome and gene set enrichment analysis was performed. Shown are enrichment plots.
NES: normalized enrichment score.
E
U87 GBM cells were treated with 20 µM LXR623 or 50 µM simvastatin (Sim) for 48 h. Thereafter, lysates were collected and analyzed for total cholesterol levels.
Shown are means and SD (n = 3). *P = 0.0145, **P = 0.0019. Statistical significance was determined by one-way ANOVA.
F
Shown is a volcano plot of patients from the TCGA (database) with high vs. low levels of ABCA1. A close-up of the most significantly down-regulated genes is
presented (mRNAs related to the electron transport chain and mitochondrial metabolism). The x-axis highlights the fold changes (log2 scale) (down-regulated
genes, negative values), whereas the y-axis indicates the level of statistical significance (shown in log10 format). Figure EV1 contains the entire volcano plot. fc:
fold changes; p: P-value.
G–J GBM12 GBM cells (short-term patient-derived xenograft), U87 GBM cells, HCT116 colonic carcinoma cells, and A375 melanoma cells were treated with the
indicated concentrations of ABT263, LXR623/GW3965, or the combination for 72 h. Thereafter, cellular viability was analyzed and statistical analysis was performed.
Shown are means and SD (n = 3–4). GBM12: *P = 0.0145, **P = 0.0019; U87: *P = 0.0108, **P = 0.0012; HCT116: **P = 0.0037, ***P = 0.0003; A375:
****P < 0.0001. Statistical significance was determined by one-way ANOVA.
K–N CI (Combination Index) value indicates whether the drug combination is additive (CI value = 1.0), synergistic (CI value < 1.0), or antagonistic. Normalized
isobolograms are presented for the combination treatments in the various solid tumor cell lines.

response to LXR agonist treatment. Our results show that LXR623
up-regulates the expression of the pro-apoptotic Bcl-2 family
member, Noxa, in glioblastoma, colon cancer, and melanoma cell
lines (Fig 3A and Appendix Fig S3B). Akin to LXR623, GW3965
caused an increase in Noxa protein levels as well (Appendix Fig
S3A). These increases were associated with an up-regulation of the
LXR downstream target, ABCA1, implying a potential relationship
between cholesterol efflux and Noxa protein levels (Fig 3B).
Specific knockdown of Noxa and BAK protects from ABT263- and
LXR-mediated apoptosis
To assess as to whether or not Noxa up-regulation is pivotal for the
cell death induction of the combination therapy (ABT263 and
LXR623), we silenced the expression of Noxa, using two Noxaspecific siRNAs, in LN229 GBM cells (Fig 3C). Knockdown of Noxa
was confirmed by capillary electrophoresis and led to a significant
attenuation of ABT263-/LXR263-mediated apoptosis (Fig 3C and D
and Appendix Fig S3C). Since Noxa binds to Mcl-1 and facilitates
BAK release, we silenced the expression of BAK as well. Suppression of BAK was confirmed by capillary electrophoresis (Fig 3D). As
expected, silencing of BAK protected LN229 cells from killing by the
combination treatment of ABT263 and LXR623 (Fig 3C and
Appendix Fig S3C). These results establish Noxa and BAK as key
elements for the combination treatment to exert apoptotic effects.
To gain more insight into the molecular events, we conducted

immunoprecipitation experiments. We immunoprecipitated BAK in
the four different conditions. In the control conditions, most BAK
protein was bound to both Mcl-1 and Bcl-xL (Fig 3E). Upon treatment with LXR623, we found a reduction of BAK binding to Bcl-xL.
As expected, this was even more pronounced in the ABT263 treatment condition in agreement with the major biological function of
this BH3 mimetic. In both single treatment conditions, BAK was
bound to Mcl-1. Notably, the combination treatment of ABT263 and
LXR623 led to a significant displacement of BAK from both Bcl-xL
and Mcl-1, in keeping with the synergistic cell death induction
elicited by the combination treatment (Fig 3E).
Activation of LXRb decreases ATP levels accompanied by an
integrated stress response
To understand as to how LXR agonists lead to this substantial
increase in Noxa levels, we reasoned that it is likely to be related to
an induction of an integrated stress response, which can be induced
by various means, including energy deprivation. Our transcriptional
and gene set enrichment analysis pointed toward a state of energy
deprivation, inhibition of mitochondrial metabolism, and an integrated stress response (Appendix Fig S4A and Fig EV1D–F). Therefore, we tested the hypothesis that LXR agonists reduce ATP levels
and found that U87 GBM and HCT116 colon carcinoma cells treated
with LXR623 or the related LXR agonist, GW3965, showed lower
ATP levels in a concentration-dependent manner, while the cells

Figure 2. Combined treatment with LXR623 and BH3 mimetics yields enhanced induction of apoptosis.
U87, T98G, and LN229 cells were treated with 1 µM ABT263, 20 µM LXR623, or the combination of both for 72 h. MeWo melanoma and HCT116 colon carcinoma
cells were treated with 1 µM ABT263, 10 µM LXR623, or the combination of both for 72 h (MeWo) and for 48 h (HCT116). Thereafter, cells were stained with
annexin V/propidium iodide and analyzed by multi-parametric flow cytometry. Shown are means and SD (n = 3). ***P = 0.0007, ****P < 0.0001. Statistical
significance was determined by one-way ANOVA.
B
Stem-like GBM cells, NCH644, NCH421k, and NCH690, were treated with 1 µM ABT263, 20 µM LXR623, or the combination of both for 48 h. Thereafter, cells were
stained with annexin V/propidium iodide and analyzed by multi-parametric flow cytometry. Shown are means and SD (n = 3). ****P < 0.0001. Statistical
significance was determined by one-way ANOVA.
C, D U87 (72 h treatment) and HCT116 (48 h treatment) were treated with 1 µM ABT263, 20 µM (U87) or 10 µM (HCT116) LXR623, or the combination of both, stained
with TMRE and analyzed by flow cytometric analysis for dissipation of mitochondrial membrane potential. Shown are means and SD (n = 3). ****P < 0.0001.
Statistical significance was determined by one-way ANOVA.
E
HCT116 colonic carcinoma cells were treated with ABT263, LXR623, or the combination of both. Whole protein lysates were collected and subjected to capillary
electrophoresis for the expression/cleavage of PARP, total caspase-9 (CP9), and Vinculin. CF: cleaved fragment; FL: full length.
F
HCT116 colonic carcinoma or NCH644 glioblastoma stem cells were treated with selective BH3 mimetics, WEHI-539 (Bcl-xL inhibitor), ABT199 (Bcl-2 inhibitor), or
A1210477 (Mcl-1 inhibitor) in the presence or absence of LXR623 for 48 h. Thereafter, cells were labeled with annexin V/propidium iodide and analyzed by multiparametric flow cytometry.
A

Source data are available online for this figure.
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Figure 3. Treatment with LXR623 regulates the expression of pro-apoptotic Noxa, and increased Noxa levels mediate enhanced sensitivity to BH3 mimetics.
A LN229, T98G, U87, U87-EGFRvIII, and HCT116 cells were treated with increasing concentrations of LXR623 for 72 h. Thereafter, protein lysates were collected and
subjected to standard Western blot (LN229, T98G, and U87) or capillary electrophoresis (U87-EGFRvIII and HCT116) for the expression of Usp9X, Mcl-1, Bcl-2, Bcl-xL,
Noxa, BIM, and/or actin and Vinculin. In U87-EGFRvIII and HCT116, Vinculin was used in lieu of actin.
B LN229, T98G, U87, U87-EGFRvIII, and HCT116 cells were treated with LXR623 as described in (A). Thereafter, protein lysates were collected and subjected to capillary
electrophoresis for the expression of ABCA1 and Vinculin.
C LN229 were transfected with siNT, siNoxa 1, siNoxa 2, or BAK siRNA for 72 h. Thereafter, cells were treated with the combination treatment of 1 µM ABT263 and
20 µM LXR623 for another 24 h. After conclusion of the treatment, cells were harvested, fixed, stained with propidium iodide, and analyzed by flow cytometry for
DNA fragmentation.
D LN229 were transfected as described in (B). Thereafter, whole-cell protein lysates were collected and analyzed by capillary electrophoresis for the expression of Noxa,
BAK, and Vinculin.
E LN229 GBM cells were treated with 10 µM LXR623 (LXR), 1 µM ABT263, or the combination for 48 h. Thereafter, protein lysates were prepared and
immunoprecipitated with an antibody against BAK. Standard Western blotting was performed (immunoprecipitation and the corresponding inputs) with antibody
against BAK and Mcl-1. The arrows highlight the specific protein bands, while stars indicate the immunoglobulin light chains.
Source data are available online for this figure.

were completely viable (Fig 4A and B, and Appendix Fig S4B and
E). In addition, we validated the reduction in ATP levels by a second
methodology, involving LC/MS, showing similar findings (Fig 4C).
Consequently, low ATP levels coupled with high AMP levels drive
the phosphorylation of AMPK at threonine 172. To validate this
claim, U87 cells were treated with increasing concentrations of
LXR623. Thereafter, cells were analyzed by capillary electrophoresis
for total AMPK and phosphorylated AMPK (threonine 172). As
anticipated, LXR623 increased the amount of phosphorylated AMPK
in a concentration-dependent manner (Fig 4D). Given that LXR
agonists suppress ATP levels, we posed the question as to whether
or not interference with cellular respiration suffices to sensitize cells
to BH3 mimetic-mediated cell death. To this end, U87 and HCT116
cells were treated with oligomycin [complex V inhibitor (ATP
synthase)], ABT263, or the combination in U87 for 48 h. Thereafter,
cells were stained with annexin V/propidium iodide and analyzed
by multi-parametric flow cytometry analysis. We observed a
remarkable synergistic induction of apoptosis in cells treated with
the combination treatment of oligomycin and ABT263
(Appendix Fig S5A and B), in keeping with our hypothesis that
energy depletion (ATP loss) and/or inhibition of mitochondrial

metabolism renders solid tumor cells susceptible to Bcl-xL
inhibition.
Since reduced energy levels may result in the induction of an
integrated stress response (Kaufman et al, 2002; Chae et al, 2012),
we tested this hypothesis by determining the levels of ATF4, GRP78,
and related markers following treatment with either LXR623 or
GW3965 and noted an increase in ATF4 at 7 and 24 h (Fig 4E, G,
and I, and Appendix Fig S5D). ATF4 is a bona fide transcription
factor and pivotal regulator that is tightly linked with stress
response signaling that executes metabolic reprogramming, regulating cell growth and survival. For these implications, it appears likely
that ATF4 may be a regulator of metabolic and cell death adaption
following modulation of LXR signaling in cancer cells. We also interrogated our GSEA and found that LXR623 induces a transcriptional
signature of ER stress (Appendix Fig S5C). To further corroborate
our findings related to ER stress, we treated U87 and HCT116 cells
with LXR agonists and isolated mRNA. Thereafter, we performed
real-time PCR analysis of various ER-stress markers (ATF3, ATF4,
XBP1, CEBPB, GRP78, and CHOP), demonstrating a consistent
increase, in keeping with a profound activation of ER-stress signaling (Appendix Fig S5E–G). In agreement with the ER-stress response

Figure 4. Activation of liver-X-receptors cause energy deprivation and activate endoplasmic reticulum stress signaling, culminating in an increase in Noxa
protein levels.
U87 cells were treated with 20 µM LXR623 for 7 h and 24 h. Thereafter, cells were stained with annexin V/propidium iodide and analyzed by multi-parametric
flow cytometry. The lower left quadrant indicates the percentage of viable cells.
B
U87 cells were treated with LXR623 as indicated for 7 h and analyzed for total ATP levels by a luminescence assay. To account for dead cells, assays were
normalized to DNA content (cell number). Shown are means and SD (n = 3–4). ***P = 0.0003, ****P < 0.0001. Statistical significance was determined by two-sided
Student’s t-test.
C
U87 cells were treated with LXR623 as indicated for 24 h. Cell lysates were prepared and subjected to LC/MS for the determination of ATP levels. Shown are means
and SD (n = 3). *P = 0.0363. Statistical significance was determined by two-sided Student’s t-test.
D
U87 cells were treated with increasing concentrations of LXR623 for 7 and 24 h. Thereafter, whole-cell protein lysates were collected and analyzed by capillary
electrophoresis for the expression of phosphorylated AMPK (threonine 172) and total AMPK.
E
U87 cells were treated with increasing concentrations of LXR623 in the presence or absence of exogenous ATP for 7 h. Thereafter, whole-cell protein lysates were
collected and analyzed by capillary electrophoresis for the expression of ATF4.
F
U87 cells were treated with increasing concentrations of LXR623 for 24 h in the presence or absence of cholesterol. Thereafter, whole-cell protein lysates were
collected and analyzed by capillary electrophoresis for the expression of phosphorylated AMPK (threonine 172) and total AMPK.
G, H Cells were treated as in (F), and whole-cell protein lysates were collected and analyzed by capillary electrophoresis for the expression of ATF4 and Vinculin (G) and
by the standard Western blot for the expression of Noxa and actin (H).
I
U87 cells were treated with increasing concentrations of LXR623. Thereafter, whole-cell protein lysates were prepared and analyzed for classical ER-stress markers,
GRP78, ATF4, and Noxa by capillary electrophoresis.
J
U87 cells were transfected with non-targeting siRNA (n.t.-siRNA), ATF3-siRNA, ATF4 siRNA, or the combination of both ATF4 and ATF3 siRNAs. After 48 h, cells were
treated with LXR623, and whole-cell protein lysates were harvested and analyzed by capillary electrophoresis for the expression of ATF3, ATF4, Noxa, and Vinculin.
A

Source data are available online for this figure.
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transcriptional signature, we detected an increase in Noxa mRNA,
suggesting that Noxa is in part regulated in a transcriptional manner
upon LXR activation (LXR623 and GW3965). This increase was
more settled in HCT116 cells treated with LXR623 (Appendix Fig
S5F). In like manner, oligomycin recapitulated the effects of LXR
activation with increases in phosphorylated AMPK (threonine 172),
Noxa, and ER-stress-related markers, GRP78, ATF4, and ATF3 in
U87 and HCT116 cells (Appendix Fig S5H and I).
To connect the underlying mechanisms of cholesterol and ATP
depletion elicited by LXR activation, we treated U87 GBM cells with
LXR623 in the presence or absence of exogenous ATP and observed
that ATP partially rescues from LXR623-mediated increase in ATF4
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protein levels (Fig 4E). Similar, albeit more pronounced findings
were seen in the presence of cholesterol, which almost completely
abrogated LXR623-driven ATF4 and Noxa increase and even
reversed enhanced phosphorylation of AMPK (Fig 4F–H). These
findings suggest a role of cholesterol in the mechanism elicited by
LXR agonists and moreover suggest that energy depletion is
involved in the activation of integrated stress response. Given that
cholesterol rescues from all features elicited by the drugs (energy
depletion, ATF4, and Noxa increase), it appears likely that cholesterol efflux is the initial event that is then followed by energy deprivation and activation of an ISR with subsequent up-regulation of
Noxa.

ª 2019 The Authors
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ATF3 and ATF4 are well established as potent transcriptional
inducers of Noxa (Wang et al, 2009; Karpel-Massler et al, 2017a).
We noted that ATF4 levels preceded the increase in Noxa levels and
24 h following treatment with LXR623 ATF4 and Noxa levels correlated (Fig 4I and a detailed time course in Fig 6J). To connect our
findings related to ISR and Noxa up-regulation, we targeted specifically the expression levels of ATF3 and ATF4 by siRNAs (both transcription factors have been described to regulate Noxa levels). To
this end, U87, LN229 GBM, or HCT116 colonic carcinoma cells were
transfected with ATF3, ATF4, or the combination of both siRNAs
and thereafter exposed to LXR623 (Fig 4J, and Appendix Fig S5J
and K). Thereafter, cells were treated with LXR623 for 48 h and
analyzed for the expression of Noxa, ATF3, and ATF4. As previously seen, LXR623 increased Noxa protein levels in the presence of
non-targeting siRNA. However, when ATF3 was silenced, we
detected a partial attenuation of LXR623-driven Noxa increase
(Fig 4J). Most prominently, knockdown of ATF4 suppressed
LXR623-mediated Noxa increase, suggesting that ATF4 is the
primary regulator of Noxa expression upon LXR receptor activation
(Fig 4J, and Appendix Fig S5J and K). In keeping with these findings
are our results related to the combined knockdown of ATF3 and
ATF4, which was less potent to attenuate LXR623-driven Noxa upregulation than ATF4 knockdown alone.
LXRb activation impairs glucose and glutamine metabolism
Next, we determined the underlying mechanisms by which LXR
activation reduces ATP levels in tumor cells. To this purpose, we
performed a polar metabolite screen, followed by pathway analysis.
This screen suggested that tricarboxylic acid (TCA) cycle as well as
pyruvate metabolism is impaired in glioblastoma cells exposed to
LXR623 (Fig 5A and B). Moreover, we detected a dysregulation of
several metabolites of the TCA cycle (Fig 5C) and a reduction of
NAD and NADH levels (Fig 5P).
Glucose and glutamine are the main energy sources in cultured
tumor cells. Therefore, we conducted glucose and glutamine tracer
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analyses to appreciate the metabolic reprogramming in the context
of LXR activation. We used uniformly labeled 13C6-glucose to trace
carbons into the TCA cycle and associated metabolites, such as
aspartic acid and glutamate. We detected a decrease in labeling of
TCA cycle intermediates by glucose carbons, including citric acid,
oxoglutarate, succinic acid, fumaric acid, and malic acid. Under
these conditions, citric acid is present in the form of several isotopologues, of which citric acid (m + 2) is indicative of glucose carbons
derived from the pyruvate dehydrogenase reaction, which results in
the loss of one carbon and suggests glucose oxidation. In contrast,
citric acid (m + 3) originates from the pyruvate carboxylase reaction, which is one of the anaplerotic reactions to fuel the TCA cycle
with carbons. LXR623 led to a decrease in citric acid (m + 2) and
(m + 3) and to reduced labeling of oxoglutaric acid, succinic acid,
fumaric acid, and malic acid (Fig 5D–H). In addition, we also found
a decrease in labeling of non-essential amino acids, glutamatic acid
and aspartic acid, glutathione, and nucleotides (Fig 5I–N). Since
aspartic acids react with carbamoyl phosphate as the initiating reaction for pyrimidine synthesis, it was not surprising to find a reduction in pyrimidine nucleotides (Fig 5L). In like manner, a reduction
of purine nucleotides was detected as well given the participation of
aspartate in purine synthesis (Fig 5M). The reduction in glutathione
labeling by glucose carbons is explained by the fact that we found
reduced glutamine labeling (by glucose carbons) and glutamine is
part of the glutathione synthesis. A summary of the carbon tracing
is provided in Fig 5O. Additional metabolites from the tracing analysis are presented in Appendix Fig S6A–E.
Given the reduction of labeling of the TCA cycle metabolites by
glucose, we asked whether glutamine metabolism is altered as well
since glutamine oxidation and anaplerosis have been described to
be critical for cancer cells (Jiang et al, 2016). For these experiments,
we used uniformly labeled 13C5-glutamine. Glutamine enters the
TCA cycle through conversion to glutamic acid and subsequently to
a-ketoglutarate, which occurs via glutaminase and glutamate dehydrogenase and/or transaminases (Appendix Fig S6F). Once
converted to a-ketoglutarate, it may either be oxidized or undergo

Figure 5. Activation of LXR reprograms central carbon metabolism of tumor cells.
U87 cells were treated with DMSO or LXR623 20 µM for 24 h. Thereafter, cells were processed for polar metabolite analysis by LC/MS. In panel (A), log10 P-values
and log2 fold change (fc) are shown. Highlighted in red are TCA cycle-related metabolites. In panel (B), metabolite pathway analysis was performed. Highlighted
(red dots) are the tricarboxylic acid cycle and pyruvate metabolism as significant and impactful pathways altered by LXR623 treatment.
C
U87 cells were treated as in (A). Shown are the levels of TCA cycle metabolites. Shown are means and SD (n = 3).
D–H U87 cells were incubated in DMEM (devoid of phenol red, glucose, pyruvate, and glutamine) supplemented with 25 mM U-13C-glucose, 4 mM glutamine, and 1.5%
dialyzed FBS in the presence or absence of 20 µM LXR623 for 24 h. Cells were then harvested for LC/MS analysis. The fractions of each different isotopologue of
each metabolite were calculated (percentage of the entire pool). Shown are the isotopologues of the TCA cycle intermediates labeled by glucose carbons and nonlabeled isotopologues (m + 0). Shown are means and SD (n = 3).
I, J
U87 cells were incubated in DMEM (devoid of phenol red, glucose, pyruvate, and glutamine) supplemented with 25 mM U-13C-glucose, 4 mM glutamine, and 1.5%
dialyzed FBS in the presence or absence of 20 µM LXR623 for 24 h. Cells were then harvested for LC/MS analysis. The fractions of each different isotopologue of
each metabolite were calculated (percentage of the entire pool). Shown are the isotopologues of non-essential amino acids (glutamatic acid and aspartic acid).
Shown are means and SD (n = 3).
K–N U87 cells were incubated in DMEM (devoid of phenol red, glucose, pyruvate, and glutamine) supplemented with 25 mM U-13C-glucose, 4 mM glutamine, and 1.5%
dialyzed FBS in the presence or absence of 20 µM LXR623 for 24 h. Cells were then harvested for LC/MS analysis. The fractions of each different isotopologue of
each metabolite were calculated (percentage of the entire pool). Shown are the isotopologues of glutathione and nucleotides. Shown are means and SD (n = 3).
O
Graphical depiction of glucose carbon tracing. Shown are the 13C-glucose carbons (red) and how they are transferred among molecules of the TCA cycle, amino
acid biosynthesis, and purine/pyrimidine synthesis. Glucose is metabolized to pyruvic acid (m + 3) (three carbons labeled). When glucose is oxidized in the TCA
cycle (m + 2), citric acid is produced (two carbons labeled). When glucose is used for anaplerosis, citric acid (m + 3) is produced (three carbons labeled). Glucose
carbons are harnessed for the biosynthesis of glutathione either through the serine/glycine pathway or the TCA cycle via oxoglutaric acid and glutamate. The
graphical presentation is representative for only one turn of the TCA cycle.
P
U87 cells were treated with DMSO or LXR623 20 µM for 24 h. Thereafter, cells were processed for polar metabolite analysis by LC/MS. Shown are the levels of NAD
and NADH2. Shown are means and SD (n = 4–6); statistical significance was determined by two-sided Student’s t-test.
A, B
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reductive carboxylation, which means that a-ketoglutarate will be
converted to citric acid (m + 5, isotopologue) in a reductive process.
Consequently, almost the entire pool of glutamine is uniformly
labeled in both control and LXR623 treatment groups (Appendix Fig
S6G). LXR623 treatment led to a decrease in labeling of several TCA
cycle metabolites by glutamine-derived carbons (Appendix Fig S6H–
L). We noted a decrease in the oxidative metabolism of glutamine
as indicated by reduced levels of citric acid (m + 4), fumarate
(m + 4), and malate (m + 4) (Appendix Fig S6H–J). However, aketoglutarate (m + 5), succinate (m + 4), and glutamate (m + 5)
labeling was increased (Appendix Fig S6H–M). In contrast, a relative
enhancement of reductive carboxylation, involving increases of
citrate (m + 5), fumarate (m + 3), malate (m + 3), succinate
(m + 3), and amino acid aspartate (m + 3), was observed by
LXR623 treatment (Appendix Fig S6H–N). While we noted a
decrease in glutathione labeling from glucose, more glutamine
carbons were incorporated into glutathione upon LXR623 treatment
(Appendix Fig S6O). Due to the partial enhanced metabolism of
glutamine (enhanced labeling of glutamate, a-ketoglutarate, and
succinate), we tested whether LXR activation results in enhanced
killing of glioblastoma cells under glutamine-deprived conditions.
Our result suggests that glutamine deprivation sensitizes for LXR
activation-driven cell death (Appendix Fig S6P). Considering the
levels of essential and non-essential amino acids, we found that
especially aspartate levels were suppressed, which is in keeping
with earlier reports, demonstrating that under conditions of inhibition with OXPHOS, aspartate becomes critical for tumors to survive
and grow (Appendix Fig S6Q; Molina et al, 2018). Overall, these
findings are consistent with a profound reprogramming of the TCA
cycle reactions by LXR agonists.
The functionality of the electron transport chain is regulated by
LXRb in cancer but not in normal cells
The proper functionality of the TCA cycle relies on functional oxidative phosphorylation. Therefore, we conducted extracellular flux
analysis and determined oxygen consumption rate (OCR) in multiple measurements (so-called mitochondrial stress assay), starting
with basal OCR followed by acute injection of oligomycin (determination of OXPHOS-dependent ATP production or coupled respiration), the uncoupling reagent FCCP (determination of reserve and
maximal respiratory capacity), and finally antimycin/rotenone (determination of mitochondria-related oxygen consumption). Stemlike GBM cells, NCH644, and established U87 and LN229 GBM cells
treated with LXR623 displayed a significant reduction in basal OCR
and OXPHOS-driven ATP production as compared to vehicle-treated
control cells (Appendix Fig S7A–L). Additional experiments were
conducted in HCT116 colon carcinoma cell lines, involving two LXR
agonists, GW3965 and LXR623. LXR623 showed a dose-dependent
reduction in basal OCR and coupled respiration (Appendix Fig S7M–
O). To appreciate the timing of these findings, we conducted a timecourse experiment. This experiment demonstrates that as early as
5 h LXR623 suppresses respiration and associated ATP production
(coupled respiration; Fig 6A–F and Appendix Fig S7D–I). To account
for the role of cholesterol in this phenomenon, we tested the impact
of LXR623 on oxidative phosphorylation in the presence or absence
of cholesterol and found that cholesterol fully reversed the effects
by LXR623 on tumor cell respiration and associated parameters,
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such as coupled respiration (ATP production by oxidative phosphorylation; Fig 6G–I). Overall, these findings indicate that LXR activation results in reprogramming of tumor cell metabolism with a
reduction of OXPHOS.
To elucidate the role of LXR agonist-mediated suppression of
oxidative phosphorylation on tumor cell survival, we undertook
rescue experiments. To this purpose, we modulated the glucose
concentration and found that as anticipated, low glucose concentrations significantly enhanced the killing effect of LXR623
(Appendix Fig S8A and B). In like manner, tumor cells cultured in
galactose (which forces the cells to oxidize the galactose-derived
glucose) displayed an increased susceptibility to LXR623 treatment
(Appendix Fig S8C). Conversely, pyruvate and aspartate rescued
from cell death mediated by LXR623, in keeping with earlier
reports by others, showing that OXPHOS-deficient cells become
auxotroph for pyruvate and dependent on the non-essential amino
acid aspartate (Appendix Fig S8E and F). Finally, exogenous
nucleotides were capable to provide a substantial rescue from
LXR623-mediated cell death as well (Appendix Fig S8D). All in all,
these observations favor that LXR agonist-driven inhibition of
OXPHOS is at least partially relevant for their cytotoxic effects on
tumor cells.
Next, we assessed the molecular underpinnings that likely lead
to this fulminant reduction in OCR and derived measurements. To
this end, we determined the protein levels of the respiratory
complexes in a time-course experiment (Fig 6J). Our findings show
that increasing concentrations of LXR agonists (LXR623 and
GW3965) elicit a suppression of OXPHOS-related complexes as early
as 5 h, coinciding with the suppression respiration (as detected by
the extracellular flux analysis and accompanied by an increase in
ATF4, followed by Noxa up-regulation; Fig 6J). Similar findings
were made in HCT116 and stem-like GBM cells, NCH644
(Appendix Fig S8G–I). The prominent suppression of SDHB (at
24 h) also fits to our finding that glutamine oxidation is blocked at
the level of succinate since in contrast to succinate, fumarate and
malate display reduced levels of the respective (m + 4) isotopologues (Appendix Fig S6I, J, and L).
To determine the mechanism as to how a reduction of OXPHOS
complexes occurs, we determined the stability of complex V in the
presence or absence of LXR activation. We found that LXR623 destabilized complex V, suggesting a post-translational mechanism by
which LXR activation suppresses respiratory complexes (Fig 6K).
Due to the fact that cholesterol is important for the fluidity of
membranes and for the proper functioning of membrane proteins,
we evaluated the respiratory complexes in the presence or absence
of LDL cholesterol and observed that LDL cholesterol protects from
LXR623-mediated suppression of OXPHOS complexes (Fig 6L).
Overall, these findings favor a direct regulation of oxidative phosphorylation by LXRs through down-regulation of the respiratory
complexes and that likely enhanced cellular efflux of cholesterol
destabilizes the respiratory complexes within the inner mitochondrial membrane.
In cancer cells, activation of LXRb has been shown to be of
highest relevance in the context of tumor growth and metastasis
suppression (Villa et al, 2016; Wang et al, 2017). This holds also
true for the model systems applied in this study. Therefore, we
asked as to whether or not activation of LXRb mediates suppression of respiration in tumor cells. To this purpose, we silenced the

EMBO Molecular Medicine 11: e10769 | 2019

11 of 20

EMBO Molecular Medicine

Trang Thi Thu Nguyen et al

A

B

C

D

E

F

G

H

J

K

M

N

I

L

O

P

Figure 6.

12 of 20

EMBO Molecular Medicine 11: e10769 | 2019

ª 2019 The Authors

Trang Thi Thu Nguyen et al

◀

EMBO Molecular Medicine

Figure 6. Activation of liver-X-receptor mediates a state of energy deprivation through inhibition of oxidative phosphorylation (OXPHOS).
U87 cells were treated with LXR623 for 1 h, 3 h, or 5 h and subjected to extracellular flux analysis on the Seahorse XFp instrument in the context of a
mitochondrial stress assay (A–C). From this assay, coupled respiration was calculated (D–F). Shown are means and SD (n = 3). **P = 0.006. Statistical significance
was determined by two-sided Student’s t-test.
G–I U87 cells were treated with LXR623, cholesterol, or the combination of both for 24 h and subjected to extracellular flux analysis on the Seahorse XFp instrument in
the context of a mitochondrial stress assay (G). From this assay, mitochondrial OCR and coupled respiration were calculated (H, I). Shown are means and SD
(n = 5). ***P = 0.0001, ****P < 0.0001. Statistical significance was determined by one-way ANOVA.
J
U87 cells were treated with DMSO or LXR623 20 µM with the indicated time point. Thereafter, whole-cell protein lysates were collected and subjected to standard
Western blot for the expression of the respiratory complexes (OXPHOS), Noxa, and ATF4. A star indicates an unspecific band.
K
U87 cells were treated with DMSO or LXR623 20 µM in the presence or absence of cycloheximide for 7 h. Thereafter, whole-cell protein lysates were collected and
the protein levels of the components of complex V were analyzed by standard Western blot.
L
U87 cells were treated with increasing concentration of LXR623 in the presence or absence of cholesterol. Thereafter, whole-cell protein lysates were collected and
analyzed the protein levels of the respiratory complexes (OXPHOS) by standard Western blot.
M–P U87 cells transduced with non-targeting or LXRb shRNA were treated with vehicle or 20 µM LXR623 for 24 h. Thereafter, extracellular flux analysis was performed
in the context of a mitochondrial stress assay. From this assay, basal respiration and coupled respiration was calculated (M, N). mRNA and protein were collected
and analyzed for the expression of LXRb mRNA (O) or LXRb protein by capillary electrophoresis (P). Shown are means and SD (n = 3–4). Statistical significance was
determined by two-sided Student’s t-test.
A–F

Source data are available online for this figure.

expression of LXRb (Fig 6O and P) and found that suppression of
LXRb levels attenuates the inhibitory effect of LXR623 on oxygen
consumption rate and coupled respiration (Fig 6M and N),
suggesting that LXRb regulates OXPHOS in cancer cells. In addition, we over-expressed LXRb and noted a suppression of oxidative phosphorylation, in keeping with our hypothesis that the
regulation of LXR by itself modulates the activity of oxidative
phosphorylation (Appendix Fig S9A and B). However, the effect of
LXRb over-expression was substantially less than the activation of
the receptors by LXR agonists since only endogenous ligands (such
as oxysterols) are available to activate the ectopically expressed
receptors. Conversely, when the receptor was silenced we detected
an increase in oxygen consumption rate (Appendix Fig S9C and
D). Akin to the U87 cells, silencing of LXRb suppressed LXR623driven inhibition of oxygen consumption rate and ATP production
in HCT116 cells, suggesting a primary role for LXRb in these
effects (Appendix Fig S9E–G).
In light of the substantial regulation of OXPHOS by LXR activation, we wondered as to whether or not non-neoplastic cells show a
similar metabolic phenotype. To this purpose, human astrocytes
were treated with LXR623 or GW3965 and analyzed for oxygen
consumption rate. Remarkably, neither LXR623 nor GW3965 regulated the oxygen consumption rate, suggesting a tumor cell-specific
phenomenon (Appendix Fig S9H and I).
Another major energetic pathway in cancer constitutes glycolysis. Therefore, it was tempting to determine the impact of LXR activation on glycolysis. Whereas we found a profound suppression of
oxidative phosphorylation triggered by LXR activation, glycolysis
was only marginally regulated by LXR activation, suggesting that
LXR activation predominantly reprograms tumor cell metabolism by
regulation of oxidative metabolism and that glycolysis is relatively
elevated as compared to oxidative phosphorylation (Appendix Fig
S9J and K).
ABT263 and LXR mediate enhanced growth reduction of a colon
cancer xenograft, a glioblastoma patient-derived xenograft, and
a BRAF V600E-mutated melanoma xenograft in nude mice
To demonstrate that Bcl-xL inhibition and activation of LXR are a
treatment strategy that is of potential translational relevance, we
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assessed its impact on growth of xenograft tumors in immunocompromised mice. To this purpose, we used the HCT116 xenograft
model and after tumor establishment four treatment groups were
formed, consisting of groups that are subjected to treatments with
vehicle, ABT263, LXR623, or the combination treatment of both
(Fig 7A and B, and Appendix Fig S10A). Our findings indicate that
both LXR623 and ABT263 reduced the growth of tumors in host
animals. However, the combination treatment was even more
potent to dampen tumor growth as compared to each compound on
its own (Fig 7A and B, and Appendix Fig S10A).
To have a better understanding about the histological findings
and the impact of the different compounds on cellular density,
proliferation, and cell death (necrosis and apoptosis), we stained
representative paraffin-embedded tumors with H&E. While vehicle,
ABT263-, or LXR623-treated tumors displayed a dense cellular architecture and an abundance of mitosis, the combination treatment
resulted in a marked lower cellular density accompanied by significantly more cell death in the form of necrosis as well as apoptosis
and a reduction in mitotic figures (Fig 7G, H, and J–L). To confirm
the impact on mitochondrial metabolism, we performed immunohistochemistry on tumors from our xenograft studies. LXR agonistrelated treatments mediate a suppression of SDHB protein levels
in vivo (Fig 7I), mirroring the in vitro findings.
To extend the findings obtained in the HCT116 colon cancer
xenograft model, we next tested the various treatments in the setting
of a patient-derived xenograft model of human glioblastoma
(GBM43). Akin to the findings in the colon cancer model, we found
that the combination treatment markedly reduced the tumor sizes in
host animals as compared to single or vehicle treatments (Fig 7C
and D, and Appendix Fig S10B).
Despite the significant advancements in immunotherapy and
BRAF inhibitor therapies, melanomas still represent a challenge in
oncology since these treatment modalities will certainly extend life
expectancy, but not provide a cure or at least a transformation to
a chronic disease stage. To this purpose, we tested our therapy in
a model system of BRAF V600E mutant melanoma, using the
A375 xenograft model. Akin to the findings above, the combination treatment of ABT263 and GW3965 reduced tumor growth
significantly stronger than each compound on its own (Fig 7E and
F, and Appendix Fig S10C), suggesting that overall our treatment
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concept of inhibition of Bcl-2 family members along with activation of LXR agonists is a viable approach for a range of solid
tumors.

Discussion
Novel treatments targeting tumor-specific therapeutic windows are
warranted. In this study, we have shown that LXR agonists, which
regulate cholesterol efflux and influx within a cell, elevate the
dependency of solid tumor cells on anti-apoptotic Bcl-2 family
members. LXR agonists represent a potentially efficacious approach
to target recalcitrant malignancies, which was exemplified in melanoma and glioblastoma (Pencheva et al, 2014; Villa et al, 2016). Of
note is the previous finding that in a preclinical model of melanoma
(syngeneic mouse model), the combination treatment of GW3965
and an immune checkpoint inhibitor exerted a significantly stronger
anti-proliferative effect than each therapeutic on its own (Pencheva
et al, 2014). Moreover, GW3965 was also effective in BRAF inhibitor-resistant melanoma models (Pencheva et al, 2014). Since
melanoma mostly kills patient through distant metastasis, it was an
important finding that GW3965 suppressed migration of melanoma
cells very efficiently in a LXRb-dependent manner (Pencheva et al,
2014). Although both melanoma and glioblastoma cell cultures
respond to GW3965 and LXR623, glioblastomas likely would benefit
more from the usage of LXR623 over GW3965 since the former has
been shown to cross the blood–brain barrier (Villa et al, 2016),
which in part might be attributed to the fact that LXR623 has a
smaller molecular weight as compared to GW3965. While healthy
astrocytes are synthesizing cholesterol, GBM cells mostly rely on
the uptake of cholesterol, which in turn renders glioblastomas
potentially susceptible to LXR agonists (Villa et al, 2016).
While the efficacy of LXR agonists is quite remarkable, the mechanisms governing these effects are less well understood. Our study
fills this gap at least partially by providing a mechanism and
through that a novel efficacious combination therapy, involving
GW3965 and LXR623. Because Bcl-2 family members are central
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regulators of cell death in malignant tumors (Preuss et al, 2013;
Souers et al, 2013; Chan et al, 2015; Faber et al, 2015; Hata et al,
2015; Johnson-Farley et al, 2015; Elgendy et al, 2016; KarpelMassler et al, 2017c), we hypothesized that LXR agonists have an
impact on their expression. While certain members of this family
are more relevant in hematological malignancies, others maintain a
pivotal role in solid tumors. Most prominently, in solid tumors BclxL has been suggested to be of higher importance than Bcl-2. Our
study is generally in line with this observation since we found that
selective inhibition of Bcl-xL enhances the effects of LXR623 to a
higher extent than inhibitors targeting Bcl-2. Our results reveal that
LXR agonists potently elevate the expression of pro-apoptotic Noxa,
thus shifting the expression ratio of Mcl-1 and Noxa. The literature
unequivocally shows that Noxa interacts with Mcl-1 and antagonizes its function by promoting the release of BAK from Mcl-1 (Oda
et al, 2000; Perez-Galan et al, 2007; Wang et al, 2009; Albershardt
et al, 2011; Du et al, 2011; Premkumar et al, 2012; Qing et al, 2012;
Yan et al, 2014). Mcl-1 levels are increased in solid malignancies
and counteract apoptosis. In line with this overall scheme, we found
that Noxa knockdown protects from cell death induced by the
combination treatment of ABT263 and LXR623. These findings are
supported by earlier observations, showing that high levels of Noxa
sensitize for BH3 mimetics-mediated cell death. Noxa expression is
regulated by multiple means, including endoplasmic reticulum
stress and associated transcription factors, such as ATF3 and ATF4,
which harbor an upstream open reading frame. We found that LXR
activation drives ER stress with an increase in ATF3 and ATF4,
which based on our rescue experiments and time courses is likely in
part mediated by LXR623-/GW3965-mediated inhibition of ATP
generation through interference with mitochondrial respiration.
Inhibition of oxidative phosphorylation by activation of LXRb is
an early, novel mechanistic observation that links this receptor to
the regulation of oxidative energy metabolism. Rescue experiments
suggest a significant role of oxidative phosphorylation on cell death
induction by LXR agonists. Our study shows that activation of LXRb
results in global suppression of mitochondrial metabolism. These
findings were supported by polar metabolite screening coupled with

Figure 7. Combined treatment with ABT263 and LXR623 leads to a growth suppression of colon carcinoma xenograft tumors, glioblastoma patient-derived
xenografts, as well as BRAF V600E-mutated melanoma xenografts.
A, B 1 × 106 HCT116 colon carcinoma cells were implanted subcutaneously. Animals were treated intraperitoneally with vehicle, LXR623 (100-200 mg/kg), ABT263
(100 mg/kg), or both agents (3 days per week for 1.5 weeks). Tumor growth curves show the development of tumor size for each treatment group. Scatter plots
display the quantitative representation of the tumor size among the different treatments toward the end of the experiment. Shown are means and SD (n ≥ 5).
*P = 0.022, **P = 0.0063, ****P < 0.0001. Statistical significance was determined by one-way ANOVA.
C, D GBM43 PDXs were implanted subcutaneously. Animals were treated intraperitoneally with vehicle, LXR623 (100 mg/kg), ABT263 (75 mg/kg), or both agents (3 days
per week for 1.5 weeks). Tumor growth curves show the development of tumor size for each treatment group. Scatter plots display the quantitative representation
of the tumor size among the different treatments toward the end of the experiment. Shown are means and SD (n ≥ 4). *P = 0.022, **P = 0.0031. Statistical
significance was determined by one-way ANOVA.
E, F A375 BRAF V600E-mutated melanomas were implanted subcutaneously. Animals were treated intraperitoneally with vehicle, LXR623 (100 mg/kg), ABT263
(75 mg/kg), or both agents (3 days per week for 1.5 weeks). Tumor growth curves show the development of tumor size for each treatment group. Scatter plots
display the quantitative representation of the tumor size among the different treatments toward the end of the experiment. Shown are means and SD (n ≥ 5).
*P = 0.0109 (GW3965 vs. Combination), *P = 0.0166 (ABT263 vs. Combination), **P = 0.0047. Statistical significance was determined by one-way ANOVA.
G
Related to the HCT116 colonic xenograft model, representative histopathological images (hematoxylin and eosin stain) are shown from each treatment group.
Scale bar: 50 µm.
H, I Sections from the same treatment groups as in (G) were stained with TUNEL and SDHB, respectively. Displayed are representative images of the staining. Scale bar
50 µm.
J–L Sections from the experiment in (A) were quantified for apoptotic bodies, number of TUNEL-positive cells, and number of mitosis per multiple high-power fields.
Shown are means and SD. In (J): *P = 0.0298, ***P = 0.0004. In (K): **P = 0.0016, ***P = 0.0001. In (L): **P = 0.004 (LXR623 vs. Combination), **P = 0.0092 (ABT263
vs. Combination). Statistical significance was determined by one-way ANOVA.
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metabolite set enrichment analysis and extracellular flux analysis
that shows substantial inhibition of oxidative phosphorylation
within 5 h of LXR agonist administration, which is fully rescued by
exogenous cholesterol and partially by silencing of LXRb. Western
blot analysis confirms the suppression of respiratory complexes
upon activation of LXRb. In agreement, the TCA cycle metabolites
were altered and carbon tracing experiments showed decreased
labeling by glucose-derived carbons. We noted a decrease in labeling of the amino acid aspartate and nucleotides by glucose carbons,
which is line with prior studies, that inhibition of OXPHOS depletes
both aspartate and nucleotides, which in turn can elicit the induction of a potential DNA-stress response (Molina et al, 2018). Through
our glutamine tracing experiment, we have found that LXR activation
renders tumor cells partially more dependent on glutamine for their
survival. Although we have not analyzed as to whether or not LXR
leads to the emergence of DNA damage, we found a substantial
decrease in NAD+ levels, which could be explained through potential
activation of the DNA-repair machinery, especially the PARP enzyme
since PARP is known to require NAD+ as a cofactor (Parrish et al,
2015). Remarkably, LXR activation does not suppress oxidative phosphorylation in human astrocytes, suggesting a tumor-selective
phenomenon that might be harnessed therapeutically. To the best of
our knowledge, these findings related to metabolism and LXR activation are novel and unique in tumor cells.
Finally, we demonstrate that LXR623 exerts anti-tumor activity
in vivo in a colon xenograft model in nude mice without significant toxicity. This effect is enhanced further in the presence of the
BH3 mimetic ABT263. These results confirm the in vitro findings
and may raise hope that such a combination treatment might have
implications for patients given the fact that both compounds have
been tested in clinical trials. However, it should be noted that
LXR623 displays side effects (Katz et al, 2009). Therefore, it may
be possible that due to the combination treatment less drug will
be necessary, thus reducing the toxicity. Additional toxicity studies
are required for this point to be confirmed. Similar results were
found in a patient-derived xenograft model system of glioblastoma
and melanoma. It is tempting to speculate as to whether or not
the selective Bcl-2 inhibitor, ABT199, would enhance the antiproliferative effects of LXR agonists as well. While this possibility
seems less likely in solid tumors, it is highly conceivable in leukemias in which ABT199 is actively pursued. In addition, myeloid
leukemia is known to be particular cholesterol-dependent. As
discussed elsewhere, ABT199 is advantageous in that it does not
affect platelets as compared to ABT263 because thrombocytes are
Bcl-xL-dependent. Overall, our results suggest that LXR agonists,
LXR623 and GW3965, affect the expression of Bcl-2 family
members and thereby modulate the sensitivity of cancer cells to
BH3 mimetics both in vitro and in vivo.

Materials and Methods
Reagents and antibodies
ABT263, WEHI-539, A1210477, GW3965, LXR623, ABT199, and
adenosine triphosphate (ATP) were obtained from Selleckchem.
Low-density lipoprotein (LDL) from human plasma was acquired
from Thermo Fisher. L-Aspartic acid sodium salt monohydrate was
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purchased from Sigma. Reagents were dissolved in dimethylsulfoxide (DMSO) (10 mM stock solution) and stored at 20°C. Final
concentrations of DMSO were below 0.1% (v/v). The following antibodies were used: ABCA1 (Abcam ab18180; 1:25), Mcl-1 (Cell
Signaling Technology (CST) 5453SS; 1:500), BAK (CST 12105S;
1:500), Bcl-2 (Abcam ab59348; 1:500), BIM (CST 2933S; 1:500), BclxL (CST 2764S; 1:500), Usp9X (CST 15751S; 1:1,000), Noxa (Millipore OP180; 1:500), b-actin (Sigma-Aldrich A1978, clone AC15;
1:2,000), ATF3 (CST 33593S; 1:500), ATF4 (CST 11815S; 1:500),
Vinculin (Abcam ab129002; 1:200), AMPK (CST 5831S; 1:25),
pAMPK (CST 2531S; 1:25), PAPRP (CST 9532S; 1:500), caspase-9
(CST 9502S; 1:500), GRP78 (CST 3177S; 1:25), HA (CST 3724S;
1:500), LXRb (Abcam ab56237; 1:25), SDHB (Abcam ab14714,
1:25), OXPHOS (Abcam ab110411; 1:500), and secondary goat antimouse IgG-HRP-linked (SC2005) and secondary goat anti-rabbit IgGHRP-linked antibodies (SC2004) were purchased from Santa Cruz
Biotechnology, Inc.
Maintenance of cells and transfections
The HCT116 (Horizon Discovery), U87 (ATCC), MDA-MB-231
(ATCC), MeWo (ATCC), LN229 (ATCC), and T98G (ATCC) cells
were grown in DMEM supplemented with 10% FBS (Gemcell) and
primocin (InvivoGen), and in a humidified air (5% CO2) at 37°C.
The cell line repositories confirmed the identities of the cell cultures
and provided testing for mycoplasma contamination. Experiments
were conducted in DMEM supplemented with 1.5% FBS and
primocin (InvivoGen). The A375 cells were maintained in RPMI
1640 supplemented with 10% FBS (Gemcell) and primocin (InvivoGen). For the experiments, cells were cultured in RPMI medium
1640 containing 1.5% FBS (non-lipoprotein-deficient) and primocin
(InvivoGen). In some experiments, lipoprotein-deficient serum
(Sigma) was used. NCH644, NCH421k, and NCH690 glioma stemlike cells (Cell Line Service: CLS, Germany) were cultured in MG-43
medium (CLS, Germany) for both maintenance and experiments.
Cells were transfected using either Lipofectamine RNAiMAX or Lipofectamine 3000 (Invitrogen) and harvested after 72 h after transfection. siPMAIP1 (siNoxa), siBAK, and siNR1H2 (siLXRb) were
purchased from Ambion. Non-targeting siRNA pool was purchased
from Dharmacon. For the shRNA lentiviral particle transduction,
cells were induced with Polybrene (Santa Cruz Biotechnology) and
were selected with puromycin (Santa Cruz Biotechnology). shRNA
NR1H2 (LXRb) or non-targeting shRNAs were purchased from Santa
Cruz Biotechnology. NR1H2 lentivirus was purchased from Applied
Biological Materials Inc.
Determination of intracellular cholesterol levels
100,000 cells (per well in a six-well plate) were treated with vehicle
or the indicated drug compounds in DMEM supplemented with
1.5% lipoprotein-deficient serum for 48 h. Following drug exposure,
cells were washed in PBS and collected. Following centrifugation,
the pelleted cells were resuspended in 100 ll assay buffer (0.1 M
potassium phosphate, 0.05 M NaCl, 5 mM cholic acid, 0.1% Triton
X-100, pH 7.4) obtained from Thermo Fisher. Thereafter, cholesterol
levels were measured by utilization of the Amplex Red Cholesterol
Assay Kit (Thermo Fisher) in alignment with the standard protocol
followed by plate reader analysis.
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Cell viability/proliferation assays
The indicated cell cultures were seeded in 96-well plates overnight
before the treatment to permit proper attachment. On the next
day, the treatments were carried out with vehicle or the indicated
single drug compounds or combination treatments in DMEM
supplemented with 1.5% FBS. Seventy-two hours after treatment,
viability analysis was performed by using the “CyQUANT Cell
Proliferation Assay” following the standard protocols for adherent
cells (provided by the manufacturer), followed by plate reader
analysis. Cholesterol rescue experiments were carried out in 1.5%
lipoprotein-deficient serum. The drug combination synergy analysis was calculated by the approach described by Chou–Talalay.
Derived from median-effect equation (single drug dose–response
related), it enables the computation of normalized isobolograms
(Chou, 2010).
Detection of mitochondrial membrane potential and
apoptosis induction
Treatments were carried out in 12-well plates. Following treatments,
cells were detached, washed, and labeled with annexin V and
propidium iodide (BD Bioscience kit, #556547), and analyzed by
flow cytometry. In other experiments, cells were detached, washed,
and fixed. After fixation, cells were stained with propidium iodide
(Propidium Iodide (PI)/RNase Staining Solution #4087, CST) and
analyzed by flow cytometry. Labeling of cells with TMRE (tetramethylrhodamine ethyl ester perchlorate) was performed following
treatments of cells in strict accordance with the protocol provided
by the manufacturer (#13296, CST, Inc), and loss of mitochondrial
membrane potential was recorded by flow cytometry. For the flow
analysis, measurements were carried out on the LSR II flow cytometer instrument (BD, NJ, USA). The FlowJo software was used for
generating graphs and data analysis (version 8.7.1, Tree Star,
Ashland, OR).
Determination of ATP levels
ATP levels were measured through LC/MS. The obtained values
were normalized to protein levels. Alternatively, an ATP luminescence assay (CellTiter-Glo) was used and the values were normalized to DNA content to account for dead cells. The DNA content
was measured by the CyQUANT Cell Proliferation Assay as
described by manual of instruction from the manufacturer. The
luminescence assays were conducted within a time frame of 7 h
(with minimal loss of viability; Karpel-Massler et al, 2017b; Tang
et al, 2017).
Capillary electrophoresis and standard Western blotting
Following treatment, cells were harvested in Laemmli sample buffer
(#1610737) or RIPA lysis buffer both supplemented with phosphatase
and protease inhibitor cocktails (Thermo Fisher Scientific). Electrophoresis was performed on gradient gels (4–12% SDS–PAGE gels;
Invitrogen). Wet transfers were carried out to PVDF membranes,
followed by blocking in milk or BSA TBST (0.1% Tween 20) and
incubation with the indicated primary antibodies overnight. Following washing, horseradish peroxidase-conjugated secondary antibodies
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were used. Vinculin and b-actin served as loading controls and were
used for normalization. Western blot emitted chemiluminescence
was recorded on the Azure (C300) Imaging System (Azure Biosystems). The Wes instrument was utilized for capillary electrophoresis,
including protein detection, in alignment with the protocols provided
by the manufacturer (ProteinSimple).
Reverse transcription real-time PCR analysis
The extraction of RNA was performed with the miRNAeasy Mini Kit
(Qiagen). Reverse transcription of RNA was carried out using the
“cDNA Synthesis kit” (OriGene). The PCR was performed with a
master mix, containing SYBR green (Applied Biosystems). The realtime PCR machine (Quantabio) was programmed as follows: 95°C
for 10 min, 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for
30 s. Upon completion of the run, data analysis was performed
(delta–delta Ct method). Genes of interest were normalized to 18S.
Fold changes relative to the controls are provided. Forward and
reverse primers are given in Table 1.
Transcriptome analysis
Microarray and subsequent gene set enrichment analysis were
performed as described earlier (Karpel-Massler et al, 2017b). The
experiment used in this study was deposited at GEO: GSE110151
and GSE110152.
Extracellular flux analysis
Oxygen consumption rate (OCR) and extracellular acidification
rate (ECAR) were measured on the Seahorse XFp or XFe24 instrument, respectively. The mitochondrial stress test was performed,
consisting of baseline measurements of OCR and in response to a
defined set of drugs (oligomycin, FCCP, antimycin/rotenone),
modulating oxidative phosphorylation. Alternatively, the glycolytic
stress test was performed according to the manufacturer’s instructions. Cells were seeded in XFe24 cell culture microplates
(Agilent) at 3 × 104 cells/well in 500 ll of DMEM containing
5 mM glucose, 1 mM glutamine, 1 mM pyruvate, and 10% FBS
and allowed to attach overnight. Cells were treated with reagents
or corresponding solvents in the medium containing 5 mM glucose,
1 mM glutamine, 1 mM pyruvate, and 1.5% FBS in the following

Table 1. Primers for real-time PCR.
Gene

Forward sequence

Reverse sequence

ATF3

CGCTGGAATCAGTCACTGTCAG

CTTGTTTCGGCACTTTGCAGCTG

ATF4

TTCTCCAGCGACAAGGCTAAGG

CTCCAACATCCAATCTGTCCCG

XBP1

CTGCCAGAGATCGAAAGAAGGC

CTCCTGGTTCTCAACTACAAGGC

CEBPB

AGAAGACCGTGGACAAGCACAG

CTCCAGGACCTTGTGCTGCGT

GRP78
(HSPA5)

CTGTCCAGGCTGGTGTGCTCT

CTTGGTAGGCACCACTGTGTTC

CHOP
(DDIT3)

GGTATGAGGACCTGCAAGAGGT

CTTGTGACCTCTGCTGGTTCTG

Noxa
(PMAIP1)

CTGGAAGTCGAGTGTGCTACTC

TGAAGGAGTCCCCTCATGCAAG
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day. The assays were performed according to the manufacturer’s
instructions (Agilent).
Liquid chromatography and mass spectrometry (LC/MS) analysis
U87 GBM cells were washed with 0.9% NaCl and were extracted
with sequential addition of ice-cold methanol/water/chloroform
(600 ll/300 ll/400 ll). Samples were vortexed and centrifuged.
The lower lipid-containing layer and the upper aqueous layer were
transferred to different tubes and evaporated to dryness under nitrogen. Dried extracts were stored at 80°C until analysis. Dried polar
extracts were reconstituted in 100 ll water, and lipid extracts were
reconstituted in 50 ll, 65:30:5 acetonitrile:2-propanol:water (v/v/v).
Both polar and lipid samples were analyzed using LC-HRMS by the
Whitehead Institute Metabolite Profiling Core Facility (Cambridge,
MA) as previously described (Franco et al, 2016; Gui et al, 2016;
Keckesova et al, 2017). Polar metabolites were analyzed by metabolite set enrichment analysis (http://www.metaboanalyst.ca).
Metabolomics and isotope tracing
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The paper explained
Problem
Advanced-stage solid cancers, such as colon carcinoma, melanoma,
and glioblastoma, require efficient treatment approaches due to the
short overall survival of patients with such tumors. Novel drug combination therapies may offer more efficient and selective targeting along
with reduced toxicity than standard chemotherapies.
Results
Here, we show that inhibition of anti-apoptotic Bcl-2 family members
together with activation of LXRs causes synthetic lethality in a variety
of solid tumors, including colorectal carcinoma, melanoma, and
glioblastoma. In xenografts, the treatment approach combining
LXR623 and ABT263 reduces tumor growth more efficiently than single
treatments. Using metabolomic approaches, we reveal a previously
undescribed link between LXRb receptor activation and regulation of
the electron transport chain, leading to stasis of central carbon metabolism (tricarboxylic acid cycle), and culminating in energy loss and
induction of an integrated stress response with activation of proapoptotic (cell death facilitating) Bcl-2-family member, Noxa.
Impact
Given that all pharmaceutical agents used in the current study have
been clinically validated, our proposed treatment approach may be
useful for patients suffering from malignant solid tumors.

Cells were serum-starved in DMEM without glucose, glutamine, and
phenol red (Thermo Fisher) for at least 1 h and then were incubated
with either 25 mM D-glucose (U-13C-glucose) (Cambridge Isotope
Laboratories, Inc) or 4 mM L-glutamine (U-13C-glutamine) for 24 h
in the presence of 1.5% dialyzed FBS (Thermo Fisher). Cells were
extracted in 80% methanol, and the supernatant was dried in a
SpeedVac concentrator (Thermo Fisher). For metabolite analysis,
the Exactive Orbitrap Mass Spectrometer (Thermo Scientific)
coupled with a Vanquish UPLC system (Thermo Scientific) was
used. The peak area for each metabolite was identified and quantitatively evaluated. Data analysis was facilitated by an in-house script
designed by the Weill Cornell Medicine Core Facility (New York,
NY) (Goncalves et al, 2018).

The TCGA analysis was performed by harnessing online computational tools, such as cBioPortal (Gao et al, 2013). The TCGA data
for colonic adenocarcinoma and glioblastoma were taken into
consideration and interrogated for high vs. low expression of
ABCA1. Fold changes were derived, and statistical analysis was
performed.

Animal maintenance and subcutaneous xenograft models

Statistical analysis

For the in vivo experiments, 6- to 8-week-old female CrTac:NCrFoxn1nu were purchased from Taconic Biosciences. The mice were
kept under controlled temperature in a 12-h (light)/12-h (dark)
cycle, provided with water and food ad libitum. The animals were
maintained in small groups (3–5 animals per cage). Following acclimation, the animals were subjected to the indicated experiments.
1 × 106 HCT116 colon carcinoma cells or A375 BRAF V600Emutated melanoma cells suspended 1:1 in Matrigel matrix (Corning Inc.) or GBM43 cryomush or cells (Sarkaria et al, 2006; Gupta
et al, 2015; Parrish et al, 2015) were implanted subcutaneously into
the flanks of 6- to 8-week-old CrTac:NCr-Foxn1nu mice as described
before (Karpel-Massler et al, 2017a). Tumors were measured with a
caliper and sizes calculated according to the standard formula:
(length * width2) * 0.5. Treatment was performed intraperitoneally
three times a week for 3 weeks. For intraperitoneal application,
ABT263 and LXR agonists were dissolved in 10% DMSO, 32%
Cremophor EL (Sigma), 8% ethanol (Pharmco-Aaper), and 50%
PBS. Representative tumors were harvested, fixed in formalin, and
thereafter embedded in paraffin. Thereafter, sections were cut that
were stained for hematoxylin and eosin (H&E stain) by standard
laboratory procedures.

Statistical significance was assessed by two-tailed Student’s t-test
or ANOVA (for multiple comparisons) using Prism version 5.04
(GraphPad, La Jolla, CA). A P ≤ 0.05 was considered statistically
significant. *P < 0.05; **P < 0.01; ***/****P < 0.001. The CompuSyn
software (ComboSyn, Inc., Paramus, NJ) was used for the drug
combination analysis including the calculation of the combination
index (CI). CI (combination index) value indicates [as to] whether the
drug combination is [either] additive (CI value = 1.0), synergistic
(CI value < 1.0), or antagonistic.
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TCGA analysis

Study approval
All procedures were in accordance with Animal Welfare Regulations
and approved by the Institutional Animal Care and Use Committee
at the Columbia University Medical Center.

Data availability
The microarray used in this study was deposited at GEO: GSE110151
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110151)
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and GSE110152 (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE110152).
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